Skip to main content
. 2022 Jun 15;11(1):2086752. doi: 10.1080/2162402X.2022.2086752

Figure 7.

Figure 7.

TLR2 inhibition promotes doxorubicin effects in impairing BC growth. Schematic representation of the mechanism of TLR2-dependent chemoresistance and of the effects of CU-CPT22 treatment in combination with doxorubicin.